Weigh! Domestic heart failure treatment "fortress" is about to be broken!

Source: public health 2017-07-28 In July 28th, nohin's Novartis (Entresto), an innovative drug for chronic heart failure, was officially approved by China food and Drug Administration (CFDA) It is expected to be listed in China at the end of 2017 official account Less than two years after the approval of the U.S Food and drug administration, the speed of landing in China is rare This is a great milestone, marking that the drug treatment of chronic heart failure patients in China is about to synchronize with Europe and the United States and enter a new era It is reported that the efficacy of nosinol ® is significantly better than that of ACEI (enalapril) in the world's largest clinical research in the field of heart failure, and it also shows good safety The global medical community is full of enthusiasm that the drug is a great breakthrough in the field of heart failure treatment, which is expected to change the overall framework of heart failure treatment that has not been innovated in the past 20 years First of all, novinol ® is the world's first angiotensin receptor enkephalinase inhibitor (Arni) Its "historic innovation" is reflected in: Novinol ® is the first drug of the class of angiotensin receptor enkephalinase inhibitors (Arni) It is composed of the enkephalinase inhibitor sacubitril and the angiotensin II receptor blocker valsartan in the molar ratio of 1:1 Both of them play a synergistic role: they enhance the natriuretic peptide system with cardioprotection and inhibit renin-angiotension-aldosterone system 1 Secondly, Novartis ® has more significant effectiveness: paradigm-hf study confirmed that compared with enalapril, Novartis ® can significantly reduce the composite end point of cardiovascular death and hospitalization risk due to heart failure by 20%, which can reduce cardiovascular death by 20%, hospitalization risk of heart failure by 21%, 2 and improve the symptoms and quality of life of patients This new treatment option and effect is of great significance to patients with hfref Heart failure is a "Fortress not yet conquered" in cardiovascular field The prevalence of heart failure in China has reached 0.9% Professor Huang Jun, a famous expert in the field of heart failure, once pointed out that heart failure is one of the five major cardiovascular diseases leading to death, and even the 5-year survival rate is lower than that of many kinds of cancers At the same time, the hospitalization rate is high, the quality of life of patients is poor, and the economic burden is heavy However, in the past ten years, there has been little progress in the drug research of chronic heart failure Although the commonly used diuretics, RAAS inhibitors, β - blockers and aldosterone receptor antagonists can improve the prognosis, the mortality rate is still high Therefore, in the face of the emergence of novinol ®, the world cardiology community has been "looking forward to it", and has given rapid response in the aspects of listing approval, guide recommendation and so on We look forward to the benefits of novostil ® to a wider range of patients around the world as soon as possible, and even to opportunities for further improvement for those who are currently receiving standard treatment (ACEI, ARB, etc.).